Compare MIRM & GSAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRM | GSAT |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 7.5B |
| IPO Year | 2019 | 2006 |
| Metric | MIRM | GSAT |
|---|---|---|
| Price | $80.08 | $61.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $92.45 | $52.75 |
| AVG Volume (30 Days) | ★ 813.7K | 775.7K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $471,794,000.00 | $262,202,000.00 |
| Revenue This Year | $53.78 | $10.93 |
| Revenue Next Year | $19.91 | $10.72 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 53.66 | 8.54 |
| 52 Week Low | $36.88 | $17.24 |
| 52 Week High | $82.58 | $74.88 |
| Indicator | MIRM | GSAT |
|---|---|---|
| Relative Strength Index (RSI) | 64.41 | 48.52 |
| Support Level | $63.23 | $61.06 |
| Resistance Level | $82.58 | $67.60 |
| Average True Range (ATR) | 3.46 | 4.31 |
| MACD | 1.47 | -1.08 |
| Stochastic Oscillator | 85.37 | 29.62 |
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Globalstar Inc is a telecommunications company that derives revenue from the provision of mobile satellite services. Mobile satellite services are typically used by customers where existing terrestrial wireline and wireless communications networks are impaired or do not exist. The company provides communications services such as two-way voice and data transmission. In addition, one-way data transmission is also offered. Both services are offered using mobile or fixed devices. The company is an owner of satellite assets. It has one reportable segment: MSS business. The company generates the vast majority of its revenue within the United States.